Method for determining hippo pathway activity

By measuring gene expression levels of specific target genes, the Hippo pathway activity is accurately assessed, addressing the lack of accurate methods and enabling personalized cancer treatment strategies.

WO2026017877A1 Publication Date: 2026-01-22INNOSIGN BV
6 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2025/070702
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-07-19
Filing Date
2025-07-18
Publication Date
2026-01-22

AI Technical Summary

Technical Problem

Current methods lack accuracy in assessing Hippo pathway activity, which is crucial for diagnosing and treating diseases such as cancer, and there is a need for methods to predict resistance to KRAS inhibitors.

Method used

Determine Hippo pathway activity by measuring the gene expression levels of specific target genes (e.g., NPPB, ANKRD1, IGFBP3, CCN2, F3, KISS1, RASSF6, SNAPC1, CCND1, CCN1, SKP2, AMOTL2, NT5E, DKK1, ITGB2, CCDC80, FJX1, AXL, TEAD4, S1 PR1, WWC1, and NUAK2) to predict tumor resistance and tailor cancer treatments.

Benefits of technology

Accurately determines Hippo pathway activity and predicts tumor resistance to KRAS inhibitors, enabling personalized cancer treatment strategies.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention describes a method to infer the Hippo cellular signaling pathway activity in a sample based on assessing the expression levels of six or more predefined target genes. The invention further describes the use of the method in prognostic and diagnostic applications and use of the method to determine or predict therapy resistance.
Need to check novelty before this filing date? Find Prior Art